[{"data":1,"prerenderedAt":216},["ShallowReactive",2],{"$f1llnbkm6wz6nz":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":22,"top_modalities":56,"top_diseases":80,"top_companies":105,"key_results":127,"trends":203,"previous_editions":212,"comparison":141,"highlighted_classes":213},1,"esmo-asia-2025","ESMO Asia","esmo-asia","ESMO Asia 2025",2025,"Oncology","2026-11-15T10:10:42Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},602,301,90,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 4":20,"Phase 2\u002F3":20,"Phase 3":21},21,16,73,2,42,[23,27,31,35,39,43,45,47,51,53],{"name":24,"count":25,"share":26},"PDCD1",55,18,{"name":28,"count":29,"share":30},"EGFR",31,10,{"name":32,"count":33,"share":34},"ERBB2",26,9,{"name":36,"count":37,"share":38},"CD274",23,8,{"name":40,"count":41,"share":42},"MET",14,5,{"name":44,"count":41,"share":42},"VEGFR2",{"name":46,"count":41,"share":42},"VEGFR4",{"name":48,"count":49,"share":50},"TUBB",13,4,{"name":52,"count":49,"share":50},"VEGFR-1",{"name":54,"count":55,"share":50},"RET",12,[57,61,64,67,69,72,75,77],{"name":58,"count":59,"share":60},"Small molecules",153,51,{"name":62,"count":15,"share":63},"Monoclonal antibodies",30,{"name":65,"count":66,"share":34},"Antibody-drug conjugates",28,{"name":68,"count":41,"share":42},"Bispecific antibodies",{"name":70,"count":71,"share":20},"Non-antibody therapeutic proteins",7,{"name":73,"count":74,"share":20},"Natural-product mixtures and botanicals",6,{"name":76,"count":42,"share":20},"Peptides",{"name":78,"count":79,"share":4},"Vaccines",3,[81,84,88,90,93,95,97,99,101,103],{"name":82,"count":83,"share":33},"non-small cell lung cancer (NSCLC)",78,{"name":85,"count":86,"share":87},"breast cancer",34,11,{"name":89,"count":26,"share":74},"gastric cancer (GC)",{"name":91,"count":92,"share":42},"hepatocellular carcinoma (HCC)",15,{"name":94,"count":49,"share":50},"head and neck squamous cell carcinoma (HNSCC)",{"name":96,"count":34,"share":79},"gastric adenocarcinoma",{"name":98,"count":34,"share":79},"gastroesophageal junction adenocarcinoma",{"name":100,"count":34,"share":79},"prostate cancer (PCa)",{"name":102,"count":38,"share":79},"colorectal cancer (CRC)",{"name":104,"count":38,"share":79},"pancreatic cancer (PC)",[106,109,111,113,115,117,119,121,123,125],{"name":107,"count":108,"share":34},"AstraZeneca",27,{"name":110,"count":26,"share":74},"Bristol Myers Squibb",{"name":112,"count":18,"share":42},"Merck",{"name":114,"count":30,"share":79},"Genentech",{"name":116,"count":30,"share":79},"Pfizer",{"name":118,"count":34,"share":79},"HUTCHMED",{"name":120,"count":34,"share":79},"Jiangsu HengRui Medicine Co., Ltd.",{"name":122,"count":38,"share":79},"Eisai",{"name":124,"count":38,"share":79},"Henlius",{"name":126,"count":71,"share":20},"BeiGene",[128,136,145,152,159,166,174,182,189,195],{"title":129,"drug":130,"company":116,"phase":132,"disease":133,"finding":134,"url":135},"199MO First-line (1L) encorafenib + cetuximab + mFOLFOX6 in East Asian patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC): Results from the phase III BREAKWATER study",{"name":131,"slug":131},"encorafenib","Phase 3","metastatic colon cancer (mCRC)","Median PFS by BICR was 14.0 vs 7.1 mo, and median OS was not estimable (NE) vs 13.7 mo for EC+mFOLFOX6 vs control.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2025.10.022",{"title":137,"drug":138,"company":141,"phase":132,"disease":142,"finding":143,"url":144},"609MO Tisotumab vedotin vs investigator’s choice of chemotherapy as second- or third-line (2L\u002F3L) treatment for Chinese patients (pts) with recurrent or metastatic cervical cancer (r\u002FmCC) in innovaTV 301",{"name":139,"slug":140},"tisotumab vedotin","tisotumab-vedotin",null,"cervical cancer (mCC)","Median (95% CI) OS was not reached (9.7 months–not estimable) with TV vs 10.7 months (6.0-not estimable) with chemotherapy (HR 0.55; 95% CI 0.27–1.15).","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2025.10.1046",{"title":146,"drug":147,"company":141,"phase":132,"disease":96,"finding":150,"url":151},"298P SHR-1701 plus CAPOX in patients with advanced gastric or gastroesophageal junction adenocarcinoma and PD-L1 combined positive score ≥1: A post-hoc analysis of a phase III study",{"name":148,"slug":149},"retlirafusp alfa","retlirafusp-alfa","Median OS was 16.7 months (95% CI, 14.4-18.5) in the SHR-1701 group versus 10.3 months (95% CI, 9.3-12.1) in the placebo group (HR=0.56; 95% CI, 0.45-0.71).","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2025.10.125",{"title":153,"drug":154,"company":156,"phase":132,"disease":82,"finding":157,"url":158},"979MO Plinabulin\u002Fdocetaxel vs. docetaxel in 2L\u002F3L EGFRwt NSCLC after platinum regimens (DUBLIN-3): Asian subgroup analysis",{"name":155,"slug":155},"plinabulin","BeyondSpring","At 24-months (Mo) follow-up after database lock (DB), the survival benefit persisted with mOS favoring DP (10.8 vs. 8.8 Mo, HR=0.80, p=0.0300), and more pronounced in non-squamous (NSQ) pts (11.4 vs. 8.4 Mo, HR=0.69, p=0.0064).","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2025.10.691",{"title":160,"drug":161,"company":141,"phase":132,"disease":163,"finding":164,"url":165},"980MO Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small-cell lung cancer (ES-SCLC): IMforte Asia subgroup results",{"name":162,"slug":162},"lurbinectedin","small cell lung cancer (SCLC)","At data cutoff (29 Jul 2024), IRF-PFS was improved with lurbi + atezo vs atezo (median, 6.3 vs 1.8 mo; unstratified HR, 0.48; 95% CI: 0.27, 0.87), as was OS (median, 16.5 vs 12.2 mo; unstratified HR, 0.81; 95% CI: 0.37, 1.75).","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2025.10.692",{"title":167,"drug":168,"company":170,"phase":132,"disease":171,"finding":172,"url":173},"1165P Safety profile of dabrafenib plus trametinib (D+T) in previously treated Chinese Mainland subgroup (CMS) population with radioactive iodine (RAI)–refractory BRAF V600E mutation–positive differentiated thyroid cancer (DTC)",{"name":169,"slug":141},"dabrafenib + trametinib","Novartis","well-differentiated thyroid cancer (WDTC)","The incidence of grade ≥3 AEs was higher in the D+T (52.8%) than the PBO arm (21.7%).","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2025.10.357",{"title":175,"drug":176,"company":118,"phase":178,"disease":179,"finding":180,"url":181},"375P Surufatinib (S) in combination with camrelizumab (C), nab-paclitaxel and gemcitabine (AG) as the first-line treatment in metastatic pancreatic cancer: Results from phase II part of a randomized, open-label, active-controlled, phase II\u002FIII study",{"name":177,"slug":177},"surufatinib","Phase 2\u002F3","pancreatic cancer (PDAC)","With the median PFS follow-up duration of 8.15 months (m), S+C+AG demonstrated superior median PFS vs AG (7.20m vs 5.52m, stratified hazard ratio [HR] 0.499, log-rank P = 0.0407).","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2025.10.201",{"title":183,"drug":184,"company":141,"phase":186,"disease":96,"finding":187,"url":188},"277MO Efficacy and safety of adebrelimab combined with S-1 plus oxaliplatin in neoadjuvant therapy for locally advanced gastric adenocarcinoma",{"name":185,"slug":185},"adebrelimab","Phase 2","The ASO group achieved significantly higher pCR rates compared to PSO group (25.45% vs 1.82%, p\u003C0.0001), with marked tumor downstaging (ypT0: 25.45% vs 1.82%; ypN0: 65.45% vs 21.82%, both p\u003C0.0001).","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2025.10.104",{"title":190,"drug":191,"company":141,"phase":186,"disease":133,"finding":193,"url":194},"205P Fruquintinib combined with TAS-102 with or without SBRT as third- or later-line treatment in metastatic colorectal cancer : Preliminary results from a prospective phase II trial",{"name":192,"slug":192},"fruquintinib","ORR was 36.4% (4\u002F11) in FTS vs 12% (3\u002F25) in FT,and mPFS was not reached in FTS vs 8.58 months (95% CI: 4.57–9.00) in FT.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2025.10.028",{"title":196,"drug":197,"company":199,"phase":200,"disease":82,"finding":201,"url":202},"986P Zongertinib in HER2-mutant advanced NSCLC: Impact of therapy line on efficacy",{"name":198,"slug":198},"zongertinib","Boehringer Ingelheim","Phase 1","In patients who received 3L zongertinib, the confirmed ORR was 75.0% (46.8–91.1)","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2025.10.698",{"summary":204,"bullets":206},[205],"Small molecules were the most frequent modality (51% of drug-linked abstracts). PDCD1 was the most frequent target (18%). Non-small cell lung cancer (NSCLC) was the most frequent disease (26%).",[207,208,209,210,211],"AstraZeneca had the largest company share (9% of drug-linked abstracts).","Antibody-drug conjugates accounted for 9% of drug-linked abstracts.","Bispecific antibodies accounted for 5% of drug-linked abstracts.","Monoclonal antibodies were the next most frequent modality (30%).","EGFR was the next most frequent target (10%).",[],[214,215],{"name":65,"count":66,"share":34,"previous_count":141,"previous_share":141,"direction":141},{"name":68,"count":41,"share":42,"previous_count":141,"previous_share":141,"direction":141},1794807930044]